2018
BiotechClub, Moscow, Russia
Application of mathematical modeling in drug research and development
Speaker: Oleg Demin
Application of QSP modeling in immuno-oncology
Speaker: Oleg Demin Jr
ICSB 2018, Lyon, France
SBML viewer is a tool for transformation of systems biology models to human-readable format
Authors: Viktoria Tkachenko , Evgeny Metelkin
An algorithm for practical identifiability analysis and confidence intervals evaluation based on constrained optimization
Authors: Ivan Borisov, Evgeny Metelkin
ACoP9, San Diego, CA, US
Quantitative systems pharmacology model for amyloid pathology investigation
Authors: Tatiana Karelina
Quantitative Systems Pharmacology (QSP) model of bispecific T-Cell engaging antibody constructs for Acute Myeloid Leukemia treatment
Authors: Oleg Demin Jr1, Svetlana Rubina1, Theresa Yuraszeck2, Khamir Mehta2, Vaishali Chudasama2, Matthias Klinger3, Cedric Dos Santos2, Oleg Demin1, Sergey Ermakov2
Affiliation: 1InSysBio, Moscow, Russia; 2Amgen Inc., Thousand Oaks, CA, USA; 3Amgen Research (Munich), Germany
Translational quantitative systems pharmacology model of tau pathology in human and mouse for immunotherapy investigation
Authors: Tatiana Karelina, Alexander Stepanov
Identification of parameters of QSP models responsible for observed variability in experimental data
Authors: Galina Kolesova, Oleg Demin
AAIC 2018, Chicago, IL, USA
Translational quantitative systems pharmacology model of tauopathies
Authors: Tatiana Karelina, Alexander Stepanov
Description of different amyloid toxic species and pathology progression by mechanistic quantitative systems pharmacology model
Authors: Tatiana Karelina, Alexander Stepanov, Alena Zhukova
PAGE 2018, Montreux, Switzerland
A semi-mechanistic model of targeted therapy for melanoma
Authors: Dmitrii Shchelokov, Oleg Demin Jr
Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology
Authors: Tatiana Karelina, Alexander Stepanov, Oleg Demin
Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment
Authors: Etienne Pigeolet1, Konstantinos Biliouris2, Ulf Neumann3, Alexandra Urusova4, Oleg Demin4, Tatiana Karelina4
Affiliation: 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Institute for Biomedical Research, Cambridge, USA; 3Novartis Institute for Biomedical Research, Basel, Switzerland; 4InSysBio, Moscow, Russia
First
Prev